Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster - 2Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- 3Russia Fields New Ulan-2 All-Terrain Tactical Vehicle
- 4Surf Spot Mechanics: Bells Beach
- 5The 12 biggest space stories of 2025 — according to you
- No injuries after blast at pro-Israel centre in the Netherlands
- The most effective method to Guarantee Thorough Inclusion in Senior Protection.
- Vote In favor of Your Number one Cell phones
- Flu cases are rising with a strain that makes older people sicker
- Fossil analysis changes what paleontologists know about how long T. rex took to grow full size
- Instructions to Warmly greet Discretion and Thoughtfulness
- Figure out How to Augment the Advantages of a Web-based Degree
- Governments take targeted action as fuel prices hit retail
- New hybrid mpox strain discovered in UK after US reports local spread
